Capstone Investment Advisors
SPRY icon

Capstone Investment Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Capstone Investment Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-72,322
Closed -$739K – 2450
2024
Q1 		$739K Buy
+72,322
New +$539K ﹤0.01% 1324

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Investment Advisors's SPRY Position: Q2 2024 in Review

Capstone Investment Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2024, closing a stake of 72,322 shares — an estimated $739K sold.

Capstone Investment Advisors first reported a position in SPRY in Q1 2024 and held it in 1 quarter. The position peaked at $739K in Q1 2024. 115 funds tracked by Wall St. Rank hold SPRY as of Q2 2024.

  • Capstone Investment Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 72,322 ARS Pharmaceuticals shares in Q2 2024, an estimated $739K.
  • Capstone Investment Advisors first reported a position in ARS Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Capstone Investment Advisors's ARS Pharmaceuticals position peaked at $739K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.